Dyne Therapeutics Inc

For the period ended Dec 31, 2024. Filed Feb 27, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Feb 27, 2025

DYN$18.62+3.0%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Balance Sheets

	December 31,
(in thousands, except share and per share data)	2024	2023
Assets
Current assets:
Cash and cash equivalents	$435,449	$121,626
Marketable securities	206,819	1,474
Prepaid expenses and other current assets	17,011	6,275
Total current assets	659,279	129,375
Property and equipment, net	5,398	4,780
Right-of-use assets	24,615	28,612
Restricted cash	1,942	2,315
Total assets	$691,234	$165,082
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable	$6,562	$22,936
Accrued expenses and other current liabilities	30,846	23,439
Lease liabilities	4,850	4,720
Total current liabilities	42,258	51,095
Lease liabilities, net of current portion	19,138	22,695
Total liabilities	61,396	73,790
Commitments and contingencies (Note 10)
Stockholders’ equity
Preferred stock, $0.0001 par value; 10,000,000 shares authorized at December 31, 2024 and 2023	—	—
Common stock, $0.0001 par value; 200,000,000 shares authorized at December 31, 2024 and 2023; 102,318,629 and 61,468,743 shares issued and outstanding at December 31, 2024 and 2023, respectively	10	6
Additional paid-in capital	1,579,750	723,796
Accumulated other comprehensive loss	6	—
Accumulated deficit	(949,928)	(632,510)
Total stockholders’ equity	629,838	91,292
Total liabilities and stockholders’ equity	$691,234	$165,082

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.